
OrganiGram Holdings OGI
€ 1.46
-3.91%
Geschäftsbericht 2024
hinzugefügt 27.12.2025
OrganiGram Holdings Betriebsaufwand 2011-2025 | OGI
Betriebsaufwand Jährlich OrganiGram Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 41.4 M | 42.4 M | 16.1 M | 8.04 M | 4.07 M | 9.35 M | - | - | - | - |
Alle Zahlen in CAD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 42.4 M | 4.07 M | 20.2 M |
Betriebsaufwand anderer Aktien in der Arzneimittelhersteller
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
197 M | $ 1.2 | 0.84 % | $ 129 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | ||
|
Cronos Group
CRON
|
154 M | $ 2.67 | 0.19 % | $ 1.39 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | ||
|
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | ||
|
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | ||
|
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | ||
|
Aurora Cannabis
ACB
|
183 M | $ 4.34 | -3.45 % | $ 86.3 M | ||
|
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M | ||
|
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | ||
|
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M | ||
|
Emergent BioSolutions
EBS
|
558 M | $ 12.24 | -1.49 % | $ 627 M | ||
|
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
196 M | $ 21.55 | -0.21 % | $ 2.05 B | ||
|
Evolus
EOLS
|
107 M | $ 6.67 | -3.41 % | $ 414 M | ||
|
Harrow Health
HROW
|
90.1 M | $ 50.49 | 0.79 % | $ 1.65 B | ||
|
China Pharma Holdings
CPHI
|
2.6 M | $ 1.23 | -6.82 % | $ 21.5 M | ||
|
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | ||
|
Organogenesis Holdings
ORGO
|
368 M | $ 5.18 | -1.9 % | $ 682 M | ||
|
Bausch Health Companies
BHC
|
4.96 B | $ 7.12 | -1.11 % | $ 2.6 B | ||
|
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 3.7 | 2.15 % | $ 4.59 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 3.94 | -4.27 % | $ 55.4 M | ||
|
Rockwell Medical
RMTI
|
31.1 M | $ 0.82 | -5.27 % | $ 19.1 M | ||
|
Pacira BioSciences
PCRX
|
279 M | $ 26.32 | -0.72 % | $ 1.22 B | ||
|
Sundial Growers
SNDL
|
102 K | $ 1.72 | -0.87 % | $ 3.37 M | ||
|
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | ||
|
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | ||
|
Veru
VERU
|
44 M | $ 2.23 | -7.25 % | $ 301 M | ||
|
Perrigo Company plc
PRGO
|
1.43 B | $ 13.88 | 0.43 % | $ 1.91 B | ||
|
ProPhase Labs
PRPH
|
47.1 M | $ 0.44 | -14.65 % | $ 6.97 M | ||
|
cbdMD
YCBD
|
28.9 M | $ 1.48 | -12.2 % | $ 6.38 M | ||
|
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
104 M | $ 4.43 | -1.77 % | $ 133 M | ||
|
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
133 M | $ 9.62 | -3.27 % | $ 683 M | ||
|
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
130 M | $ 5.73 | -1.97 % | $ 234 M | ||
|
SCYNEXIS
SCYX
|
67.5 M | $ 0.63 | 7.32 % | $ 30.1 M | ||
|
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
1.52 B | $ 9.25 | -3.62 % | $ 5.72 B | ||
|
TherapeuticsMD
TXMD
|
9.82 M | $ 1.71 | -1.72 % | $ 17.9 M |